Skip to content
OpenCapital
Get started

Kiniksa Pharmaceuticals International, plc KNSA Financing Cash Flow

Financing Cash Flow at other companies

Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
-$14.13M-198%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
$18.77M+7,175%
Apogee Therapeutics, Inc. logo
Apogee Therapeutics, Inc.APGE
$411.17M+66,004%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$549.89M+812%
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$57.26M+2,504%
LQD
Liquidia CorporationLQDA
-$18.05M-174%

Other financials

Income statement

See full
Revenue$214.3M+55.5%
Gross profit$193.5M+61.3%
Operating income$29.3M+121%
Net income$22.6M+165%
EPS (diluted)$0.27+145%

Balance sheet

See full
Cash & equivalents$190.0M+20.9%
Total debt$9.0M-9.0%
Total equity$605.7M+32.4%
Total assets$825.3M+37.7%

Cash flow

See full
Operating cash flow$50.2M+125%
CapEx$161.0K+62.6%
Free cash flow$50.0M+125%

Valuation

See full
Market cap$4.58B+128%

Profitability

See full
Gross margin89.3%+3.5pp
Operating margin12.4%+10.2pp
Net margin9.7%+7.6pp
FCF margin21.8%+12.2pp

Returns & leverage

See full
Return on equity13.7%+11.3pp
Debt / equity0×0.0×
Current ratio3.8×+0.1×

Where this comes from

Reported directly by Kiniksa Pharmaceuticals International, plc in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The official record: Kiniksa Pharmaceuticals International, plc’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about Kiniksa Pharmaceuticals International, plc's financing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Kiniksa Pharmaceuticals International, plc's financing cash flow?
Kiniksa Pharmaceuticals International, plc (KNSA) reported financing cash flow of $6.07M in Q1 2026.
How has Kiniksa Pharmaceuticals International, plc's financing cash flow changed year-over-year?
Kiniksa Pharmaceuticals International, plc's financing cash flow increased by 119.4% year-over-year, from $2.77M to $6.07M.
What is the long-term trend for Kiniksa Pharmaceuticals International, plc's financing cash flow?
Over 4 years (2021 to 2025), Kiniksa Pharmaceuticals International, plc's financing cash flow has grown at a 53.9% compound annual growth rate (CAGR), from $5.89M to $33.02M.
What does financing cash flow mean?
Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.